224 related articles for article (PubMed ID: 25155755)
1. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
Haling JR; Sudhamsu J; Yen I; Sideris S; Sandoval W; Phung W; Bravo BJ; Giannetti AM; Peck A; Masselot A; Morales T; Smith D; Brandhuber BJ; Hymowitz SG; Malek S
Cancer Cell; 2014 Sep; 26(3):402-413. PubMed ID: 25155755
[TBL] [Abstract][Full Text] [Related]
2. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.
Brennan DF; Dar AC; Hertz NT; Chao WC; Burlingame AL; Shokat KM; Barford D
Nature; 2011 Apr; 472(7343):366-9. PubMed ID: 21441910
[TBL] [Abstract][Full Text] [Related]
3. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
4. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
5. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
[TBL] [Abstract][Full Text] [Related]
6. BRAF has a kinase-independent role in MAPK signaling.
Cancer Discov; 2014 Nov; 4(11):OF22. PubMed ID: 25367964
[TBL] [Abstract][Full Text] [Related]
7. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
9. MEK drives BRAF activation through allosteric control of KSR proteins.
Lavoie H; Sahmi M; Maisonneuve P; Marullo SA; Thevakumaran N; Jin T; Kurinov I; Sicheri F; Therrien M
Nature; 2018 Feb; 554(7693):549-553. PubMed ID: 29433126
[TBL] [Abstract][Full Text] [Related]
10. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
Park E; Rawson S; Li K; Kim BW; Ficarro SB; Pino GG; Sharif H; Marto JA; Jeon H; Eck MJ
Nature; 2019 Nov; 575(7783):545-550. PubMed ID: 31581174
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
12. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
13. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
14. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
15. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
16. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
17. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
[No Abstract] [Full Text] [Related]
18. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
[TBL] [Abstract][Full Text] [Related]
19. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of a B-Raf Kinase α-Helix Critical for the Activity of MEK Kinase in MAPK Signaling.
Nguyen D; Lin LY; Zhou JO; Kibby E; Sia TW; Tillis TD; Vapuryan N; Xu MR; Potluri R; Shin Y; Erler EA; Bronkema N; Boehlmer DJ; Chung CD; Burkhard C; Zeng SH; Grasso M; Acevedo LA; Marmorstein R; Fera D
Biochemistry; 2020 Dec; 59(50):4755-4765. PubMed ID: 33272017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
